Group begins work on community projects

The 2016-17 class of Leadership Hancock County broke up into groups recently and began work on their community projects. The six projects are an eclectic collection of initiatives sponsored by nonprofit groups and will help the classmates develop their teamwork skills.

Portola Pharmaceuticals Announces FDA Accepts New Drug Application…

Portola Pharmaceuticals, Inc.A today announced that the U.S. Food and Drug Administration accepted Portola’s New Drug Application granting priority review for betrixaban, an oral, once-daily Factor Xa inhibitor anticoagulant, for extended-duration prophylaxis of venous thromboembolism in acute medically ill patients with risk factors for VTE. A priority review shortens the FDA review timeline to six months from the standard review period of 10 months.

Ten Supplements to Avoid

At Beauty Headlines we are passionate about cutting through the advertising and marketing noise while delivering clear simple info and advice on health and beauty matters in the 21st century. Check BeautyHeadlines.com daily for the latest trends, tips, and honest advice without all the noise.

Ten Supplements to Avoid

At Beauty Headlines we are passionate about cutting through the advertising and marketing noise while delivering clear simple info and advice on health and beauty matters in the 21st century. Check BeautyHeadlines.com daily for the latest trends, tips, and honest advice without all the noise.

Novelion files European marketing application for metreleptin for leptin deficiency

Novelion Therapeutics’ European subsidiary files a Marketing Authorization Application seeking approval for Orphan Drug-tagged metreleptin as replacement therapy to treat complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy and in a subgroup of patients with partial lipodystrophy . If approved, the product will be marketed under the brand name MYALEPTA.

Akebia sells rights to anemia drug to Japan’s Otsuka

Drug developer Akebia Therapeutics Inc said on Tuesday it had signed a co-development and marketing deal worth up to $1 billion with Japan’s Otsuka Holdings Co Ltd. Akebia said the deal would give it the funds needed to develop vadadustat, its experimental drug to treat anemia associated with chronic kidney disease. Akebia’s shares were up 17.1 percent at $9.78 in early trading.

Advertisers and crib manufacturers fail to adhere to safe sleep recommendations for infants

A new study from the University of Alabama at Birmingham shows that national magazine advertisements and manufacturers of infant cribs continue to depict unsafe sleep environments, despite longtime guidelines established by the American Academy of Pediatrics to protect against SIDS and other sleep-related deaths. “It is important that health care providers, advertisers and crib manufacturers come together to educate parents and caregivers about safe sleep environments for children,” said Bradley Troxler, M.D., assistant professor and director of the UAB Pediatric Pulmonary Center who treats patients at Children’s of Alabama.

Tetraphase Pharmaceuticals Provides Regulatory and Clinical Update for Eravacycline

Tetraphase Pharmaceuticals, Inc. , a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant infections, today provided a regulatory and clinical development update for eravacycline, the Company’s lead antibiotic candidate with potent activity against MDR pathogens, which is being developed for the treatment of serious and life-threatening bacterial infections. During the second half of 2017, Tetraphase plans to submit a Marketing Authorization Application to the European Medicines Agency for IV eravacycline for the treatment of cIAI.

SK Chemicals’ hemophilia drug approved in Canada

SK Chemicals, the biopharmaceuticals unit of South Korea’s SK Group, has obtained regulatory approval to sell its hemophilia treatment in Canada, marking another step forward in breaking into overseas markets. SK Chemicals said Sunday that Health Canada, the country’s drug regulator, has granted marketing and sales approval for Afstyla, a biologic drug for hemophilia developed by SK Chemicals and licensed out to Australian biotech firm CSL Ltd. in 2009.